KRAS mutations drive roughly a quarter of all human cancers, yet approved KRAS inhibitors deliver only short-lived responses before resistance emerges, and combination strategies have been limited by severe toxicity.
Researchers at Stanford have designed, in silico, a series of new human IL-2 mutants that have biased actions on different immune cell subsets, and confer increased signaling potency compared to natural IL-2.
Systemic chemotherapy remains the main treatment option for malignant tumors, including breast cancer. Nevertheless, the frequent development of resistance in tumors often causes treatment failure and patient death, presenting a significant challenge in cancer treatment.
Researchers at Stanford have developed compounds for inhibiting the epidermal growth factor receptor (EGFR) that covalently label a nucleophile that has not been targeted before.
Researchers at Stanford have developed a novel method of using macrocyclic compounds that act as inhibitors of epidermal growth factor receptor (EGFR) for the treatment or prevention of kinase-mediated disorders, including cancer and other proliferation diseases.
Stanford researchers have discovered that Neat1, a long non-coding RNA, regulates degradation of the MYC protein, revealing a new target for treating MYC-dependent cancers.
Stanford researchers have patented methods to improve phagocytosis, the process by which macrophages clear protein aggregates, dying cells, and debris, to treat age-related diseases.
Stanford researchers in the Cochran Lab have patented a potential pancreatic cancer therapeutic approach using novel agents that bind tightly to and inhibit a cancer factor called LIF (leukemia inhibitory factor).
Researchers at Stanford University have demonstrated rapid and accurate identification of extracellular vesicles (EVs) from different cell lines using an AI-assisted optical platform.
High-grade gliomas, including glioblastoma and diffuse midline glioma are the most common malignant brain tumor types and leading causes of brain-tumor-related death in adults and children, respectively.
Stanford researchers in Prof. Corinne Beinat's lab have developed a novel radiotracer, [18F]hGTS13, for non-invasive imaging of system xc- activity, enabling the identification of ferroptosis-sensitive cancers and monitoring the efficacy of ferroptosis-inducing therapies.
Stanford researchers in Prof. Corinne Beinat's lab have developed a small molecule radiotheranostic for targeted radionuclide therapy of cancers overexpressing system xc-, such as high-grade glioma and non-small cell lung cancer (NSCLC).
Overweight and obesity are linked to an increased risk and worsened outcome from many cancers, including colorectal, pancreatic and breast cancer, but the mechanisms responsible for these phenomena are unknown.
Researchers in Dr. Michelle Monje-Deisseroth's lab at Stanford have identified therapeutic targets for drug development to limit the spread of high-grade gliomas (HGGs).